Clinical Trial Update: Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial combining AlloStim with an anti-PD-L1 agent for fourth-line metastatic microsatellite-stable colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• AlloStim (allogeneic immunotherapy)
• Anti-PD-L1 (PD-L1 inhibitor)

Snippet

Sponsor: Mirror Biologics, Inc. | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: WITHDRAWN